文献速递核素与放射性配体治疗神经核医学

高级别脑膜瘤中SSTR2a、FAP、HER2和HER3作为潜在放射性核素治疗靶点的表达

Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-16

该研究对58例CNS WHO 2级和3级脑膜瘤样本进行SSTR2a、FAP、HER2和HER3的免疫组化染色,并与(表)遗传学亚型和生存进行关联分析。SSTR2a在43/55(78.2%)可评估样本中表达,FAP在15/58(25.9%)中表达,HER2和HER3各仅1例(1.7%)表达。SSTR2a表达与TRAF7野生型相关(p=0.034),FAP表达在CNS WHO 3级(对比2级;p<0.001)、NF2突变(p=0.032)或CDKN2A/B缺失(p=0.013)样本中更常见;FAP和SSTR2a表达与总生存无显著关联(p>0.05)。

要点

  • SSTR2a在78.2%(43/55)可评估高级别脑膜瘤中表达,FAP在25.9%(15/58)中表达,HER2/HER3各仅1例。
  • FAP表达在CNS WHO 3级(对比2级;p<0.001)、NF2突变(p=0.032)和CDKN2A/B缺失(p=0.013)样本中更常见。
  • SSTR2a和FAP表达与总生存无显著关联(p>0.05),靶点表达空间异质性应纳入放射性配体治疗设计考虑。

核心结论

  • SSTR2a和FAP在高级别脑膜瘤样本中以不同比例表达,不同脑膜瘤亚型间的表达差异强调需要生物标志物来改进患者选择。
  • 靶点表达的空间异质性应在放射性配体治疗设计中加以考虑。

研究设计与样本

  • 对58例CNS WHO 2级和3级脑膜瘤样本进行SSTR2a、FAP、HER2/HER3免疫组化染色,并与DNA甲基化分析的(表)遗传学肿瘤亚型、遗传改变和生存进行关联分析。

主要发现

  • SSTR2a(膜/胞质)表达见于43/55(78.2%)可评估样本,FAP表达见于15/58(25.9%)可评估样本,HER2和HER3各仅1例标本(1.7%)表达。
  • 膜性SSTR2a表达强、中、弱分别见于18例(32.7%)、12例(21.8%)和11例(20.0%)样本。
  • SSTR2a表达更均一,主要见于细胞密度较高区域;FAP免疫反应主要见于肿瘤间质和细胞密度较低区域。
  • SSTR2a免疫反应与TRAF7野生型状态相关(p=0.034)。
  • FAP表达在CNS WHO 3级脑膜瘤中较CNS WHO 2级更常见(p<0.001),在NF2突变(p=0.032)或CDKN2A/B缺失(p=0.013)样本中较野生型更常见;FAP和SSTR2a表达(有 vs. 无)与总生存无显著关联(p>0.05)。

关键数值与推荐

  • SSTR2a表达43/55(78.2%),FAP表达15/58(25.9%),HER2和HER3表达各1例(1.7%)。
  • 膜性SSTR2a表达强18例(32.7%)、中等12例(21.8%)、弱11例(20.0%)。
  • SSTR2a免疫反应与TRAF7野生型相关,p=0.034。
  • FAP表达与CNS WHO 3级(对比2级)相关,p<0.001;与NF2突变相关,p=0.032;与CDKN2A/B缺失相关,p=0.013。
  • FAP和SSTR2a表达(有 vs. 无)与总生存无显著关联,p>0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce. METHODS: CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival. RESULTS: Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status (p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations (p = 0.032) or CDKN2A/B deletions (p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival (p > 0.05). CONCLUSION: SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mair MJ, Hartenbach S, Tomasich E, et al. Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma. Eur J Nucl Med Mol Imaging. 2025. PMID: 39969538. doi:10.1007/s00259-025-07075-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。